137 results on '"Eldem, B"'
Search Results
2. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial
- Author
-
Mercuri, Eugenio Maria, Deconinck, N., Mazzone, Elena Stacy, Nascimento, A., Oskoui, M., Saito, K., Vuillerot, C., Baranello, Giovanni, Boespflug-Tanguy, O., Goemans, N., Kirschner, J., Kostera-Pruszczyk, A., Servais, L., Gerber, M., Gorni, K., Khwaja, O., Kletzl, H., Scalco, R. S., Staunton, H., Yeung, W. Y., Martin, Craig, Fontoura, P., Day, J. W., Volpe, J. J., Posner, J., Kellner, U., Quinlivan, R., Fuerst-Recktenwald, S., Marquet, A., Mulhardt, N., Trundell, D., Daron, A., Delstanche, S., Romain, B., Dal Farra, F., Schneider, O., Balikova, I., Delbeke, P., Joniau, I., Tahon, V., Wittevrongel, S., De Vos, E., Casteels, I., De Waele, L., Cassiman, C., Prove, L., Kinoo, D., Vancampenhout, L., Van Den Hauwe, M., Van Impe, A., Prufer de Queiroz Campos Araujo, A., Chacon Pereira, A., Nardes, F., Haefeli, L., Rossetto, J., Almeida Pereira, J., Ferreira Rebel, M., Campbell, C., Sharan, S., Mcdonald, W., Scholtes, C., Mah, J., Sframeli, M., Chiu, A., Hagel, J., Beneish, R., Pham, C., Toffoli, D., Arpin, S., Turgeon Desilets, S., Wang, Y., Hu, C., Huang, J., Qian, C., Shen, L., Xiao, Y., Zhou, Z., Li, H., Wang, S., Xiong, H., Chang, X., Dong, H., Liu, Y., Sang, T., Wei, C., Wen, J., Cao, Y., Lv, X., Zhao, J., Li, W., Qin, L., Barisic, N., Galiot Delic, M., Ivkic, P. K., Vukojevic, N., Kern, I., Najdanovic, B., Skugor, M., Gidaro, T., Seferian, A., De Lucia, Sara Sofia, Barreau, E., Mnafek, N., Momtchilova, M. M., Peche, H., Valherie, C., Grange, A., Lilien, C., Milascevic, D., Tachibana, S., Ravelli, C., Cardas, R., Vanden Brande, L., Davion, J. -B., Coopman, S., Bouacha, I., Debruyne, P., Defoort, S., Derlyn, G., Leroy, F., Danjoux, L., Guilbaud, J., Desguerre, I., Barnerias, C., Semeraro, M., Bremond-Gignac, D., Bruere, L., Rateaux, M., Deladriere, E., Germa, V., Pereon, Y., Magot, A., Mercie, S., Billaud, F., Le Goff, L., Letellier, G., Portefaix, A., Fontaine, S., De-Montferrand, C., Le-Goff, L., Saidi, M., Bouzid, N., Barriere, A., Tinat, M., Dreesbach, M., Lagreze, W., Michaelis, B., Molnar, F., Seger, D., Vogt, S., Bertini, Enrico Silvio, D'Amico, Adele, Petroni, S., Bonetti, A. M., Carlesi, A., Mizzoni, I., Bruno, C., Priolo, E., Rao, G., Morando, S., Tacchetti, P., Zuffi, A., Comi, G. P., Brusa, R., Corti, Serafino, Daniele, V., Govoni, A., Magri, F., Minorini, V., Osnaghi, S. G., Abbati, F., Fassini, F., Foa, M., Lopopolo, A., Meneri, M., Zoppas, F., Parente, V., Masson, R., Bianchi Marzoli, Stefania, Santarsiero, Rocco Domenico, Garcia Sierra, M., Tremolada, G., Arnoldi, M. T., Vigano, M., Zanin, Renata, Amorelli, Giulia Maria, Barresi, C., D'Amico, Guglielmo, Orazi, Lorenzo, Coratti, Giorgia, Haginoya, K., Kato, A., Morishita, Y., Kira, R., Akiyama, K., Goto, M., Mori, Y., Okamoto, M., Tsutsui, S., Takatsuji, Y., Tanaka, A., Komaki, H., Suzuki, I., Takeuchi, M., Todoroki, D., Watanabe, S., Omori, M., Matsubayashi, T., Inakazu, E., Nagura, H., Suzuki, A., Osaka, H., Ohashi, M., Ishikawa, N., Harada, Y., Fudeyasu, K., Hirata, K., Michiue, K., Ueda, K., Yashiro, S., Seki, M., Sano, N., Uemura, A., Fukuyama, K., Matsumoto, Y., Miyazaki, H., Shibata, M., Kobayashi, K., Nakamura, Y., Takeshima, Y., Kuma, M., Fraczek, A., Jedrzejowska, M., Lusakowska, A., Czeszyk-Piotrowicz, A., Hautz, W., Rakusiewicz, K., Burlewicz, M., Gierlak-Wojcicka, Z., Kepa, M., Sikorski, A., Sobieraj, M., Mazurkiewicz-Beldzinska, M., Lemska, A., Modrzejewska, S., Koberda, M., Stodolska-Koberda, U., Waskowska, A., Kolendo, J., Sobierajska-Rek, A., Steinborn, B., Dalz, M., Grabowska, J., Hajduk, W., Janasiewicz-Karachitos, J., Klimas, M., Stopa, M., Gajewska, E., Pusz, B., Vlodavets, D., Melnik, E., Leppenen, N., Yupatova, N., Monakhova, A., Papina, Y., Shidlovsckaia, O., Milic Rasic, V., Brankovic, V., Kosac, A., Djokic, O., Jaksic, V., Pepic, A., Martinovic, J., Munell Casadesus, F., Tizzano, E., Martin Begue, N., Wolley Dod, C., Subira, O., Planas Pascual, B., Toro Tamargo, E., Madruga Garrido, M., Medina Romero, J. D., Salinas, M. P., Nascimento Osorio, A., Diaz Cortes, A., Jimenez Ganan, E., Suh, S. D., Medina Cantillo, J., Moya, O., Padros, N., Roca Urraca, S., Gonzalez Valdivia, H., Pascual Pascual, S., de Manuel, S., Noval Martin, S., Burnham, P., Espinosa Garcia, S., Martinez Moreno, M., Topaloglu, H., Oncel, I., Eroglu Ertugrul, N., Konuskan, B., Eldem, B., Kadayifcilar, S., Alemdaroglu, I., Ayse Karaduman, A., Tunca Yilmaz, O., Bilgin, N., Sari, S., Chiriboga, C., Kane, S., Lee, J., Rome-Martin, D., Beres, S., Duong, T., Gee, R., Dunaway Young, S., Mercuri E. (ORCID:0000-0002-9851-5365), Mazzone E. S., Baranello G., Martin C., De Lucia S., Bertini E., D'Amico A., Corti S., Bianchi Marzoli S., Santarsiero D., Zanin R., Amorelli G. M., D'Amico G., Orazi L., Coratti G. (ORCID:0000-0001-6666-5628), Mercuri, Eugenio Maria, Deconinck, N., Mazzone, Elena Stacy, Nascimento, A., Oskoui, M., Saito, K., Vuillerot, C., Baranello, Giovanni, Boespflug-Tanguy, O., Goemans, N., Kirschner, J., Kostera-Pruszczyk, A., Servais, L., Gerber, M., Gorni, K., Khwaja, O., Kletzl, H., Scalco, R. S., Staunton, H., Yeung, W. Y., Martin, Craig, Fontoura, P., Day, J. W., Volpe, J. J., Posner, J., Kellner, U., Quinlivan, R., Fuerst-Recktenwald, S., Marquet, A., Mulhardt, N., Trundell, D., Daron, A., Delstanche, S., Romain, B., Dal Farra, F., Schneider, O., Balikova, I., Delbeke, P., Joniau, I., Tahon, V., Wittevrongel, S., De Vos, E., Casteels, I., De Waele, L., Cassiman, C., Prove, L., Kinoo, D., Vancampenhout, L., Van Den Hauwe, M., Van Impe, A., Prufer de Queiroz Campos Araujo, A., Chacon Pereira, A., Nardes, F., Haefeli, L., Rossetto, J., Almeida Pereira, J., Ferreira Rebel, M., Campbell, C., Sharan, S., Mcdonald, W., Scholtes, C., Mah, J., Sframeli, M., Chiu, A., Hagel, J., Beneish, R., Pham, C., Toffoli, D., Arpin, S., Turgeon Desilets, S., Wang, Y., Hu, C., Huang, J., Qian, C., Shen, L., Xiao, Y., Zhou, Z., Li, H., Wang, S., Xiong, H., Chang, X., Dong, H., Liu, Y., Sang, T., Wei, C., Wen, J., Cao, Y., Lv, X., Zhao, J., Li, W., Qin, L., Barisic, N., Galiot Delic, M., Ivkic, P. K., Vukojevic, N., Kern, I., Najdanovic, B., Skugor, M., Gidaro, T., Seferian, A., De Lucia, Sara Sofia, Barreau, E., Mnafek, N., Momtchilova, M. M., Peche, H., Valherie, C., Grange, A., Lilien, C., Milascevic, D., Tachibana, S., Ravelli, C., Cardas, R., Vanden Brande, L., Davion, J. -B., Coopman, S., Bouacha, I., Debruyne, P., Defoort, S., Derlyn, G., Leroy, F., Danjoux, L., Guilbaud, J., Desguerre, I., Barnerias, C., Semeraro, M., Bremond-Gignac, D., Bruere, L., Rateaux, M., Deladriere, E., Germa, V., Pereon, Y., Magot, A., Mercie, S., Billaud, F., Le Goff, L., Letellier, G., Portefaix, A., Fontaine, S., De-Montferrand, C., Le-Goff, L., Saidi, M., Bouzid, N., Barriere, A., Tinat, M., Dreesbach, M., Lagreze, W., Michaelis, B., Molnar, F., Seger, D., Vogt, S., Bertini, Enrico Silvio, D'Amico, Adele, Petroni, S., Bonetti, A. M., Carlesi, A., Mizzoni, I., Bruno, C., Priolo, E., Rao, G., Morando, S., Tacchetti, P., Zuffi, A., Comi, G. P., Brusa, R., Corti, Serafino, Daniele, V., Govoni, A., Magri, F., Minorini, V., Osnaghi, S. G., Abbati, F., Fassini, F., Foa, M., Lopopolo, A., Meneri, M., Zoppas, F., Parente, V., Masson, R., Bianchi Marzoli, Stefania, Santarsiero, Rocco Domenico, Garcia Sierra, M., Tremolada, G., Arnoldi, M. T., Vigano, M., Zanin, Renata, Amorelli, Giulia Maria, Barresi, C., D'Amico, Guglielmo, Orazi, Lorenzo, Coratti, Giorgia, Haginoya, K., Kato, A., Morishita, Y., Kira, R., Akiyama, K., Goto, M., Mori, Y., Okamoto, M., Tsutsui, S., Takatsuji, Y., Tanaka, A., Komaki, H., Suzuki, I., Takeuchi, M., Todoroki, D., Watanabe, S., Omori, M., Matsubayashi, T., Inakazu, E., Nagura, H., Suzuki, A., Osaka, H., Ohashi, M., Ishikawa, N., Harada, Y., Fudeyasu, K., Hirata, K., Michiue, K., Ueda, K., Yashiro, S., Seki, M., Sano, N., Uemura, A., Fukuyama, K., Matsumoto, Y., Miyazaki, H., Shibata, M., Kobayashi, K., Nakamura, Y., Takeshima, Y., Kuma, M., Fraczek, A., Jedrzejowska, M., Lusakowska, A., Czeszyk-Piotrowicz, A., Hautz, W., Rakusiewicz, K., Burlewicz, M., Gierlak-Wojcicka, Z., Kepa, M., Sikorski, A., Sobieraj, M., Mazurkiewicz-Beldzinska, M., Lemska, A., Modrzejewska, S., Koberda, M., Stodolska-Koberda, U., Waskowska, A., Kolendo, J., Sobierajska-Rek, A., Steinborn, B., Dalz, M., Grabowska, J., Hajduk, W., Janasiewicz-Karachitos, J., Klimas, M., Stopa, M., Gajewska, E., Pusz, B., Vlodavets, D., Melnik, E., Leppenen, N., Yupatova, N., Monakhova, A., Papina, Y., Shidlovsckaia, O., Milic Rasic, V., Brankovic, V., Kosac, A., Djokic, O., Jaksic, V., Pepic, A., Martinovic, J., Munell Casadesus, F., Tizzano, E., Martin Begue, N., Wolley Dod, C., Subira, O., Planas Pascual, B., Toro Tamargo, E., Madruga Garrido, M., Medina Romero, J. D., Salinas, M. P., Nascimento Osorio, A., Diaz Cortes, A., Jimenez Ganan, E., Suh, S. D., Medina Cantillo, J., Moya, O., Padros, N., Roca Urraca, S., Gonzalez Valdivia, H., Pascual Pascual, S., de Manuel, S., Noval Martin, S., Burnham, P., Espinosa Garcia, S., Martinez Moreno, M., Topaloglu, H., Oncel, I., Eroglu Ertugrul, N., Konuskan, B., Eldem, B., Kadayifcilar, S., Alemdaroglu, I., Ayse Karaduman, A., Tunca Yilmaz, O., Bilgin, N., Sari, S., Chiriboga, C., Kane, S., Lee, J., Rome-Martin, D., Beres, S., Duong, T., Gee, R., Dunaway Young, S., Mercuri E. (ORCID:0000-0002-9851-5365), Mazzone E. S., Baranello G., Martin C., De Lucia S., Bertini E., D'Amico A., Corti S., Bianchi Marzoli S., Santarsiero D., Zanin R., Amorelli G. M., D'Amico G., Orazi L., and Coratti G. (ORCID:0000-0001-6666-5628)
- Abstract
Background: Risdiplam is an oral small molecule approved for the treatment of patients with spinal muscular atrophy, with approval for use in patients with type 2 and type 3 spinal muscular atrophy granted on the basis of unpublished data. The drug modifies pre-mRNA splicing of the SMN2 gene to increase production of functional SMN. We aimed to investigate the safety and efficacy of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy. Methods: In this phase 3, randomised, double-blind, placebo-controlled study, patients aged 2–25 years with confirmed 5q autosomal recessive type 2 or type 3 spinal muscular atrophy were recruited from 42 hospitals in 14 countries across Europe, North America, South America, and Asia. Participants were eligible if they were non-ambulant, could sit independently, and had a score of at least 2 in entry item A of the Revised Upper Limb Module. Patients were stratified by age and randomly assigned (2:1) to receive either daily oral risdiplam, at a dose of 5·00 mg (for individuals weighing ≥20 kg) or 0·25 mg/kg (for individuals weighing <20 kg), or daily oral placebo (matched to risdiplam in colour and taste). Randomisation was conducted by permutated block randomisation with a computerised system run by an external party. Patients, investigators, and all individuals in direct contact with patients were masked to treatment assignment. The primary endpoint was the change from baseline in the 32-item Motor Function Measure total score at month 12. All individuals who were randomly assigned to risdiplam or placebo, and who did not meet the prespecified missing item criteria for exclusion, were included in the primary efficacy analysis. Individuals who received at least one dose of risdiplam or placebo were included in the safety analysis. SUNFISH is registered with ClinicalTrials.gov, NCT02908685. Recruitment is closed; the study is ongoing. Findings: Between Oct 9, 2017, and Sept 4, 2018, 180 patients were rand
- Published
- 2022
3. Defining Nonadherence and Nonpersistence to Anti-Vascular Endothelial Growth Factor Therapies in Neovascular Age-Related Macular Degeneration
- Author
-
Okada, M, Wong, TY, Mitchell, P, Eldem, B, Talks, SJ, Aslam, T, Daien, V, Rodriguez, FJ, Gale, R, Barratt, J, Finger, RP, Loewenstein, A, Okada, M, Wong, TY, Mitchell, P, Eldem, B, Talks, SJ, Aslam, T, Daien, V, Rodriguez, FJ, Gale, R, Barratt, J, Finger, RP, and Loewenstein, A
- Abstract
IMPORTANCE: Poor adherence or persistence to treatment can be a barrier to optimizing clinical practice (real-world) outcomes to intravitreal injection therapy in patients with neovascular age-related macular degeneration (nAMD). Currently, there is a lack of consensus on the definition and classification of adherence specific to this context. OBJECTIVE: To describe the development and validation of terminology on patient nonadherence and nonpersistence to anti-vascular endothelial growth factor therapy. DESIGN, SETTING, AND PARTICIPANTS: Following a systematic review of currently used terminology in the literature, a subcommittee panel of retinal experts developed a set of definitions and classification for validation. Definitions were restricted to use in patients with nAMD requiring intravitreal anti-vascular endothelial growth factor therapy. Validation by the full nAMD Barometer Leadership Coalition was established using a modified Delphi approach, with predetermined mean scores of 7.5 or more signifying consensus. Subsequent endorsement of the definitions was provided from a second set of retinal experts, with more than 50% members agreeing or strongly agreeing with all definitions. MAIN OUTCOMES AND MEASURES: Development of consensus definitions for the terms adherence and persistence and a classification system for the factors associated with treatment nonadherence or nonpersistence in patients with nAMD. RESULTS: Nonadherence was defined as missing 2 or more treatment or monitoring visits over a period of 12 months, with a visit considered missed if it exceeded more than 2 weeks from the recommended date. Nonpersistence was defined by nonattendance or an appointment not scheduled within the last 6 months. The additional terms planned discontinuation and transfer of care were also established. Reasons for treatment nonadherence and nonpersistence were classified into 6 dimensions: (1) patient associated, (2) condition associated, (3) therapy associated, (4)
- Published
- 2021
4. Graefes Arch Clin Exp Ophthalmol
- Author
-
Korobelnik, Jean-François, Loewenstein, A., ELDEM, B., JOUSSEN, A. M., Koh, A., LAMBROU, G. N., Lanzetta, P., Li, Xiaojian, LOVESTAM-ADRIAN, M., Navarro, R., OKADA, A. A., Pearce, I., RODRIGUEZ, F. J., WONG, D. T., Wu, L., Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), and CHU Bordeaux [Bordeaux]
- Subjects
Coronavirus ,Ophthalmology ,Vision Academy ,Retinal disease ,COVID-19 ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Recommendations ,[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs - Abstract
International audience; Purpose: There is an urgent need to address how to best provide ophthalmic care for patients with retinal disease receiving intravitreal injections with anti-vascular endothelial growth factor agents during the ongoing global COVID-19 pandemic. This article provides guidance for ophthalmologists on how to deliver the best possible care for patients while minimizing the risk of infection.Methods: The Vision Academy’s Steering Committee of international retinal disease experts convened to discuss key considerations for managing patients with retinal disease during the COVID-19 pandemic. After reviewing the existing literature on the issue, members put forward recommendations that were systematically refined and voted on to develop this guidance.Results: The considerations focus on the implementation of steps to minimize the exposure of patients and healthcare staff to COVID-19. These include the use of personal protective equipment, adherence to scrupulous hygiene and disinfection protocols, pre-screening to identify symptomatic patients, and reducing the number of people in waiting rooms. Other important measures include triaging of patients to identify those at the greatest risk of irreversible vision loss and prioritization of treatment visits over monitoring visits where possible. In order to limit patient exposure, ophthalmologists should refrain from using treatment regimens that require frequent monitoring.Conclusion: Management of patients with retinal disease receiving intravitreal injections during the COVID-19 pandemic will require adjustment to regular clinical practice to minimize the risk of exposure of patients and healthcare staff, and to prioritize those with the greatest medical need. The safety of patients and healthcare staff should be of paramount importance in all decision-making.
- Published
- 2020
- Full Text
- View/download PDF
5. CURRENT CONCEPTS AND MODALITIES FOR MONITORING THE FELLOW EYE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: An Expert Panel Consensus.
- Author
-
Wong, TY, Lanzetta, P, Bandello, F, Eldem, B, Navarro, R, Lövestam-Adrian, M, Loewenstein, A, Wong, TY, Lanzetta, P, Bandello, F, Eldem, B, Navarro, R, Lövestam-Adrian, M, and Loewenstein, A
- Abstract
PURPOSE: The presence of neovascular age-related macular degeneration (nAMD) in one eye is a major risk factor for the development of disease in the fellow eye. Several methods exist to help physicians monitor the fellow eye, with new technologies becoming increasingly available. METHODS: We provide an overview of modalities for nAMD monitoring, including advances in home-based options, and review their utility for fellow-eye monitoring, based on a review of the literature and a consensus of retinal experts. RESULTS: Studies demonstrate the importance of early detection of nAMD in the fellow eye so that interventions can be made before significant vision loss occurs. A series of techniques exist for the early detection of nAMD including chart-based methods and imaging devices. The increased availability of home-based methods has presented an opportunity for patients to monitor their vision at home. CONCLUSION: Frequent monitoring of the fellow eye in patients with unilateral nAMD is of critical importance to prevent vision loss and maintain quality of life. Patients should be examined every 3 to 4 months from the time of choroidal neovascularization diagnosis and encouraged to monitor their vision at home using home-based technologies where available, to provide the best opportunity for early detection.
- Published
- 2020
6. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration Chroma and Spectri Phase 3 Randomized Clinical Trials
- Author
-
Holz, Fg, Sadda, Sr, Busbee, B, Chew, Ey, Mitchell, P, Tufail, A, Brittain, C, Ferrara, D, Gray, S, Honigberg, L, Martin, J, Tong, B, Ehrlich, Js, Bressler, Nm, Sola, Ff, Schlottmann, P, Zambrano, A, Zeolite, C, Arnold, J, Gillies, M, Luckie, A, Schneltzer, N, de Zaeytijd, J, Boyd, S, Cruess, A, Kertes, P, Lalonde, L, Maberley, D, Laugesen, C, Bodaghi, B, Cohen, Sy, Francais, C, Souied, E, Tadayoni, R, Altay, L, Eter, N, Feltgen, N, Framme, C, Grisanti, S, Holz, F, Pauleikhoff, D, Seres, A, Vajas, A, Varsanyi, B, Boscia, F, Parravano, Mc, Ricci, F, Viola, F, Rechy, Dl, Morales, V, Dijkman, G, Schlingemann, R, Reategui, G, Raczynska, D, Romanowska-Dixon, B, Teper, S, Kacerik, M, Lipkova, B, Oddelenie, O, Mikova, H, Araiz, J, Arias, L, Mataix, J, Mones, J, Montero, J, Sararols, L, Michels, S, Brand, C, Dhillon, B, Agarwal, A, Alfaro, V, Baker, B, Berger, B, Bhisitkul, R, Blodi, B, Boyer, D, Brooks, Hl, Burgess, S, Busquets, M, Callanan, D, Chan, C, Chang, J, Chen, S, Combs, J, Dhoot, D, Dugel, P, Eichenbaum, D, Feist, R, Ferrone, P, Fine, H, Fortun, J, Fox, Ga, Fu, A, Gentile, R, Ghorayeb, G, Gill, M, Gonzalez, V, Gordon, C, Gupta, S, Hampton, R, Heier, J, Hershberger, V, Higgins, P, Ie, D, Isernhagen, R, Katz, R, Kokame, G, Kwun, R, Lee, P, Lee, S, Mansour, S, Marcus, D, Maturi, R, Michels, M, Moore, J, Nielsen, J, Novalis, G, Ober, M, Olsen, K, Patel, S, Pieramici, D, Raskauskas, P, Rofagha, S, Ruby, A, Schneiderman, T, Schwartz, S, Shah, R, Sheth, V, Singerman, L, Singh, R, Sjaarda, R, Stoller, G, Stoltz, R, Suner, I, Tabassian, A, Tarantola, R, Thach, A, Ufret-Vincenty, R, Wirthlin, R, Witkin, A, Wong, R, Wood, M, Zheutlin, J, Alezzandrini, A, Cartier, Mm, Chauhan, D, Chen, F, Gilhotra, J, Guymer, R, Kwan, A, Schmidt-Erfurth, U, Jacob, J, Postelmans, L, Larsen, M, Garcher, Cc, Bocage, C, Devin, F, Kodjikian, L, Korobelnik, Jf, Said, Sm, Weber, M, Agostini, H, Auffarth, G, Bartz-Schmidt, U, Bell, K, Gamulescu, A, Hattenbach, L, Lohmann, Cp, Wolf, A, Nemeth, J, Vamosi, P, Bandello, F, Eandi, C, Lanzetta, P, Nicolo, M, Staurenghi, G, Virgili, G, Franco, Rg, Estudillo, Jr, Hoyng, C, Fernandez, C, Guzman, M, Lujan, S, Herba, E, Kaluzny, J, Misiuk-Hojlo, M, Nawrocki, J, Carneiro, A, Figueira, J, Silva, R, Vaz-Pereira, S, Abdulaeva, E, Erichev, V, Zolotarev, A, Cernak, A, Figueroa, M, Gallego-Pinazo, R, Garcia-Layana, A, Ulla, Fg, Navarro, R, Ortiz, Jm, Imaz, Rt, Kvanta, A, Hatz, K, Wolf, S, Eldem, B, Kir, N, Mentes, J, Saatci, O, Yilmaz, G, Bailey, C, Banerjee, S, Browning, A, Esposti, S, Gale, R, Ghanchi, F, Jackson, T, Lotery, A, Mahmood, S, Mohamed, Q, Narendran, N, Pearce, I, Williams, M, Abraham, P, Abrams, G, Adrean, S, Antoszyk, A, Baker, C, Breazeale, R, Bridges, Wz, Brown, Dm, Calzada, J, Campochiaro, P, Chaudhry, N, Clark, L, Connolly, B, Csaky, K, Do, D, Dreyer, R, Durant, W, Eaton, A, Feiner, L, Ferreyra, H, Flaxel, C, Foxman, S, Freund, Kb, Gonzales, Cr, Gordon, A, Halperin, L, Ho, A, Holekamp, N, Husain, D, Jain, N, Javid, C, Johnson, M, Kiss, S, Lad, E, Leng, T, Liu, M, London, N, Madow, B, Miller, D, Morse, L, Ohr, M, Oliver, S, Pearlman, J, Ray, Sk, Regillo, C, Rosa, R, Rosenfeld, P, Saperstein, D, Sarraf, D, Shildkrot, Y, Suan, E, Weishaar, P, Wieland, M, Williams, D, Williams, J, Wykoff, Cc, Ophthalmology, ACS - Atherosclerosis & ischemic syndromes, ANS - Cellular & Molecular Mechanisms, and ANS - Systems & Network Neuroscience
- Subjects
Male ,0301 basic medicine ,medicine.medical_specialty ,Visual acuity ,Population ,Visual Acuity ,Urology ,law.invention ,Lesion ,Immunoglobulin Fab Fragments ,Macular Degeneration ,03 medical and health sciences ,0302 clinical medicine ,Atrophy ,Double-Blind Method ,Randomized controlled trial ,law ,Settore MED/30 ,Geographic Atrophy ,80 and over ,medicine ,Humans ,Prospective Studies ,Fluorescein Angiography ,Prospective cohort study ,education ,Aged ,Original Investigation ,Aged, 80 and over ,education.field_of_study ,business.industry ,Middle Aged ,Macular degeneration ,Complement Factor D ,Female ,Intravitreal Injections ,Treatment Outcome ,medicine.disease ,Clinical trial ,Ophthalmology ,030104 developmental biology ,030221 ophthalmology & optometry ,medicine.symptom ,business - Abstract
Importance Geographic atrophy (GA) secondary to age-related macular degeneration is a leading cause of visual disability in older individuals. A phase 2 trial suggested that lampalizumab, a selective complement factor D inhibitor, reduced the rate of GA enlargement, warranting phase 3 trials. Objective To assess the safety and efficacy of lampalizumab vs sham procedure on enlargement of GA. Design, Setting, and Participants Two identically designed phase 3 double-masked, randomized, sham-controlled clinical trials, Chroma and Spectri, enrolled participants from August 28, 2014, to October 6, 2016, at 275 sites in 23 countries. Participants were aged 50 years or older, with bilateral GA and no prior or active choroidal neovascularization in either eye and GA lesions in the study eye measuring 2.54 to 17.78 mm 2 with diffuse or banded fundus autofluorescence patterns. Interventions Participants were randomized 2:1:2:1 to receive 10 mg of intravitreous lampalizumab every 4 weeks, sham procedure every 4 weeks, 10 mg of lampalizumab every 6 weeks, or sham procedure every 6 weeks, through 96 weeks. Main Outcomes and Measures Safety and efficacy assessed as mean change from baseline in GA lesion area at week 48 from centrally read fundus autofluorescence images of the lampalizumab arms vs pooled sham arms, in the intent-to-treat population and by complement factor I–profile genetic biomarker. Results A total of 906 participants (553 women and 353 men; mean [SD] age, 78.1 [8.1] years) were enrolled in Chroma and 975 participants (578 women and 397 men; mean [SD] age, 77.9 [8.1] years) were enrolled in Spectri; 1733 of the 1881 participants (92.1%) completed the studies through 48 weeks. The adjusted mean increases in GA lesion area from baseline at week 48 were 1.93 to 2.09 mm 2 across all groups in both studies. Differences in adjusted mean change in GA lesion area (lampalizumab minus sham) were −0.02 mm 2 (95% CI, −0.21 to 0.16 mm 2 ; P = .80) for lampalizumab every 4 weeks in Chroma, 0.16 mm 2 (95% CI, 0.00-0.31 mm 2 ; P = .048) for lampalizumab every 4 weeks in Spectri, 0.05 mm 2 (95% CI, −0.13 to 0.24 mm 2 ; P = .59) for lampalizumab every 6 weeks in Chroma, and 0.09 mm 2 (95% CI, −0.07 to 0.24 mm 2 ; P = .27) for lampalizumab every 6 weeks in Spectri. No benefit of lampalizumab was observed across prespecified subgroups, including by complement factor I–profile biomarker. Endophthalmitis occurred after 5 of 12 447 injections (0.04%) or in 5 of 1252 treated participants (0.4%) through week 48. Conclusions and Relevance In Chroma and Spectri, the largest studies of GA conducted to date, lampalizumab did not reduce GA enlargement vs sham during 48 weeks of treatment. Results highlight the substantial and consistent enlargement of GA, at a mean of approximately 2 mm 2 per year. Trial Registration ClinicalTrials.gov Identifier:NCT02247479andNCT02247531
- Published
- 2018
- Full Text
- View/download PDF
7. Evaluation of Choroidal Thickness, Choroidal Vascularity Index and Peripapillary Retinal Nerve Fiber Layer in Patients with Juvenile Systemic Lupus Erythematosus
- Author
-
Ağın, A., primary, Kadayıfçılar, S., additional, Sönmez, H.E., additional, Baytaroğlu, A., additional, Demir, S., additional, Sağ, E., additional, Özen, S., additional, and Eldem, B., additional
- Published
- 2018
- Full Text
- View/download PDF
8. Case of the month
- Author
-
Saatçi, I., Arslan, S., Topçu, M., Eldem, B., Karagöz, T., and Saatçi, Ü.
- Published
- 1996
- Full Text
- View/download PDF
9. Barriers To Management of Diabetic Eye Diseases In Turkey: Dr Barometer Survey
- Author
-
Beykoz, V, primary, Kahveci, B, additional, Saylan, M, additional, and Eldem, B, additional
- Published
- 2017
- Full Text
- View/download PDF
10. Evaluation of Choroidal Thickness, Choroidal Vascularity Index and Peripapillary Retinal Nerve Fiber Layer in Patients with Juvenile Systemic Lupus Erythematosus.
- Author
-
Ağın, A., Kadayıfçılar, S., Sönmez, H. E., Baytaroğlu, A., Demir, S., Sağ, E., Özen, S., and Eldem, B.
- Subjects
CHOROID diseases ,SYSTEMIC lupus erythematosus ,ADRENOCORTICAL hormones ,ANTIPHOSPHOLIPID syndrome ,TOMOGRAPHY - Abstract
Objective The aim of this study was to conduct a detailed ophthalmological examination in children with systemic lupus erythematosus (jSLE), including choroidal thickness (ChT), choroidal vascularity index (CVI) and peripapillary retinal nerve fiber layer (RNFL). Methods The study included all jSLE patients (n = 21) diagnosed according to the Systemic Lupus International Collaborating Clinics classification criteria between January 2017 and April 2017, and an age- and gender-matched control group (n = 21). The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) was used to assess disease activity. After routine eye examinations, ChT at five points (750 µ and 1500 µ from the center of the fovea both in the temporal and nasal quadrants and under the fovea), total subfoveal choroidal area (TCA), luminal area (LA), stromal area (SA), CVI and RNFL thickness at the optic disc were evaluated. Results One patient had active ocular involvement in the form of episcleritis. Another patient had corticosteroid-induced cataract. The median age of the patients was 16 years (6-19 years). ChT at five points, TCA, LA and SA were found to be higher in patients with jSLE, whereas RNFL thickness and CVI were similar to those of the healthy control individuals. No correlation was determined between optical coherence tomography findings, SLEDAI and the immunological parameters (antinuclear antibodies, anti-double-stranded DNA, complements 3 and 4, extracted nuclear antigen antibody, antiphospholipid antibody). Intraretinal and subretinal fluid was not present in any of the patients. Conclusion The choroid was thicker in patients with jSLE than in the control group. The study results suggest that jSLE may affect the choroid. Ophthalmological evaluation is important in SLE patients, even in the absence of relevant complaints. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
11. Annual Cost of Illness of Macular Edema (ME) Secondary to Branch Retinal Vein Occlusion (BRVO) in Turkey
- Author
-
Sar, C, primary, Malhan, S, additional, Oksuz, E, additional, Eldem, B, additional, Unlu, N, additional, Alp, MN, additional, Durukan, AH, additional, Erdal, E, additional, and Kahveci, B, additional
- Published
- 2016
- Full Text
- View/download PDF
12. Burden of Visual Impairment Due to Myopic Choroidal Neovascularisation (MCNV) in Turkey
- Author
-
Sar, C, primary, Malhan, S, additional, Oksuz, E, additional, Eldem, B, additional, Unlu, N, additional, Alp, MN, additional, Ozmert, E, additional, Durukan, AH, additional, Erdal, E, additional, and Kahveci, B, additional
- Published
- 2016
- Full Text
- View/download PDF
13. Cost-Effectiveness of Intravitreal Aflibercept (IVT-AFL) in Treatment of Macular Edema (ME) Secondary to Branch Retinal Vein Occlusion (BRVO)
- Author
-
Sar, C, primary, Malhan, S, additional, Oksuz, E, additional, Eldem, B, additional, Unlu, N, additional, Alp, MN, additional, Ozmert, E, additional, Durukan, AH, additional, Erdal, E, additional, and Kahveci, B, additional
- Published
- 2016
- Full Text
- View/download PDF
14. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration
- Author
-
Silva, R. de, Axer-Siegel, R., Eldem, B., Guymer, R., Kirchhof, B., Papp, A., Seres, A., Gekkieva, M., Nieweg, A., Pilz, S., and Hoyng, C.B.
- Subjects
genetic structures ,Evaluation of complex medical interventions Genomic disorders and inherited multi-system disorders [NCEBP 2] - Abstract
Item does not contain fulltext OBJECTIVE: To evaluate long-term safety of intravitreal ranibizumab 0.5-mg injections in neovascular age-related macular degeneration (nAMD). DESIGN: Twenty-four-month, open-label, multicenter, phase IV extension study. PARTICIPANTS: Two hundred thirty-four patients previously treated with ranibizumab for 12 months in the EXCITE/SUSTAIN study. METHODS: Ranibizumab 0.5 mg administered at the investigator's discretion as per the European summary of product characteristics 2007 (SmPC, i.e., ranibizumab was administered if a patient experienced a best-corrected visual acuity [BCVA] loss of >5 Early Treatment Diabetic Retinopathy Study letters measured against the highest visual acuity [VA] value obtained in SECURE or previous studies [EXCITE and SUSTAIN], attributable to the presence or progression of active nAMD in the investigator's opinion). MAIN OUTCOME MEASURES: Incidence of ocular or nonocular adverse events (AEs) and serious AEs, mean change in BCVA from baseline over time, and the number of injections. RESULTS: Of 234 enrolled patients, 210 (89.7%) completed the study. Patients received 6.1 (mean) ranibizumab injections over 24 months. Approximately 42% of patients had 7 or more visits at which ranibizumab was not administered, although they had experienced a VA loss of more than 5 letters, indicating either an undertreatment or that factors other than VA loss were considered for retreatment decision by the investigator. The most frequent ocular AEs (study eye) were retinal hemorrhage (12.8%; 1 event related to study drug), cataract (11.5%; 1 event related to treatment procedure), and increased intraocular pressure (6.4%; 1 event related to study drug). Cataract reported as serious due to hospitalization for cataract surgery occurred in 2.6% of patients; none was suspected to be related to study drug or procedure. Main nonocular AEs were hypertension and nasopharyngitis (9.0% each). Arterial thromboembolic events were reported in 5.6% of the patients. Five (2.1%) deaths occurred during the study, none related to the study drug or procedure. At month 24, mean BCVA declined by 4.3 letters from the SECURE baseline. CONCLUSIONS: The SECURE study showed that ranibizumab administered as per a VA-guided flexible dosing regimen recommended in the European ranibizumab SmPC at the investigator's discretion was well tolerated over 2 years. No new safety signals were identified in patients who received ranibizumab for a total of 3 years. On average, patients lost BCVA from the SECURE study baseline, which may be the result of disease progression or possible undertreatment. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
- Published
- 2013
15. The Cost-Effectiveness (CE) of Intravitreal Aflibercept (IVT-AFL) in the Treatment of Diabetic Macular Edema (DME) in Turkey
- Author
-
Deger, C, primary, Ozdemir, O, additional, Eldem, B, additional, Unlu, N, additional, Alp, MN, additional, Saatci, AO, additional, Ozmert, E, additional, Altintas, AK, additional, Sermet, F, additional, Erdal, E, additional, Sar, C, additional, Asan, S, additional, Sumer, F, additional, Parali, E, additional, and Ozel, O, additional
- Published
- 2015
- Full Text
- View/download PDF
16. The Cost-Of-Disease (Cod) In Central Retinal Vein Occlusion (Crvo) In Turkey: An Expert Panel Approach For Estimation of Costs
- Author
-
Deger, C, primary, Ozdemir, O, additional, Eldem, B, additional, Unlu, N, additional, Alp, MN, additional, Saatci, AO, additional, Ozmert, E, additional, Erdal, E, additional, Sar, C, additional, Asan, S, additional, Sumer, F, additional, Parali, E, additional, and Ozel, O, additional
- Published
- 2015
- Full Text
- View/download PDF
17. The Cost-Of-Disease (Cod) In Wet Age-Related Macular Degeneration (Wamd) In Turkey: An Expert Panel Approach for Estimation of Costs
- Author
-
Deger, C, primary, Ozdemir, O, additional, Eldem, B, additional, Unlu, N, additional, Alp, MN, additional, Saatci, AO, additional, Ozmert, E, additional, Erdal, E, additional, Sar, C, additional, Asan, S, additional, Sumer, F, additional, Parali, E, additional, and Ozel, O, additional
- Published
- 2015
- Full Text
- View/download PDF
18. The Cost-Of-Disease (Cod) In Diabetic Macular Edema (Dme) In Turkey: An Expert Panel Approach for Estimation of Costs
- Author
-
Deger, C, primary, Ozdemir, O, additional, Eldem, B, additional, Unlu, N, additional, Alp, MN, additional, Saatci, AO, additional, Ozmert, E, additional, Altintas, AK, additional, Sermet, F, additional, Erdal, E, additional, Sar, C, additional, Asan, S, additional, Sumer, F, additional, Parali, E, additional, and Ozel, O, additional
- Published
- 2015
- Full Text
- View/download PDF
19. Cost-effectiveness of Aflibercept in the treatment of Central Retinal Vein Occlusion in Turkey
- Author
-
Tunalioglu, A., primary, Ozdemir, O., additional, Eldem, B., additional, Unlu, N., additional, Alp, M.N., additional, Saatci, A.O., additional, Ozmert, E., additional, Deger, C., additional, Asan, S., additional, Sumer, F., additional, Parali, E., additional, Ozel, M.O., additional, Erdal, E., additional, and Sar, C., additional
- Published
- 2015
- Full Text
- View/download PDF
20. Cost-effectiveness of Aflibercept in the treatment of wet age-related Macular Degeneration in Turkey
- Author
-
Tunalioglu, A., primary, Ozdemir, O., additional, Eldem, B., additional, Unlu, N., additional, Alp, M.N., additional, Saatci, A.O., additional, Ozmert, E., additional, Deger, C., additional, Asan, S., additional, Sumer, F., additional, Parali, E., additional, Ozel, M.O., additional, Erdal, E., additional, and Sar, C., additional
- Published
- 2015
- Full Text
- View/download PDF
21. PSS46 - Barriers To Management of Diabetic Eye Diseases In Turkey: Dr Barometer Survey
- Author
-
Beykoz, V, Kahveci, B, Saylan, M, and Eldem, B
- Published
- 2017
- Full Text
- View/download PDF
22. PSS37 - Cost-Effectiveness of Intravitreal Aflibercept (IVT-AFL) in Treatment of Macular Edema (ME) Secondary to Branch Retinal Vein Occlusion (BRVO)
- Author
-
Sar, C, Malhan, S, Oksuz, E, Eldem, B, Unlu, N, Alp, MN, Ozmert, E, Durukan, AH, Erdal, E, and Kahveci, B
- Published
- 2016
- Full Text
- View/download PDF
23. PSS30 - Annual Cost of Illness of Macular Edema (ME) Secondary to Branch Retinal Vein Occlusion (BRVO) in Turkey
- Author
-
Sar, C, Malhan, S, Oksuz, E, Eldem, B, Unlu, N, Alp, MN, Durukan, AH, Erdal, E, and Kahveci, B
- Published
- 2016
- Full Text
- View/download PDF
24. PSS28 - Burden of Visual Impairment Due to Myopic Choroidal Neovascularisation (MCNV) in Turkey
- Author
-
Sar, C, Malhan, S, Oksuz, E, Eldem, B, Unlu, N, Alp, MN, Ozmert, E, Durukan, AH, Erdal, E, and Kahveci, B
- Published
- 2016
- Full Text
- View/download PDF
25. Stabilizing the sternum using an absorbable copolymer plate after open surgery for pectus deformities: New techniques to stabilize the anterior chest wall after open surgery for pectus excavatum
- Author
-
Yuksel, M., primary, Bostanci, K., additional, and Eldem, B., additional
- Published
- 2011
- Full Text
- View/download PDF
26. PDB51 - The Cost-Effectiveness (CE) of Intravitreal Aflibercept (IVT-AFL) in the Treatment of Diabetic Macular Edema (DME) in Turkey
- Author
-
Deger, C, Ozdemir, O, Eldem, B, Unlu, N, Alp, MN, Saatci, AO, Ozmert, E, Altintas, AK, Sermet, F, Erdal, E, Sar, C, Asan, S, Sumer, F, Parali, E, and Ozel, O
- Published
- 2015
- Full Text
- View/download PDF
27. PSS21 - Cost-effectiveness of Aflibercept in the treatment of wet age-related Macular Degeneration in Turkey
- Author
-
Tunalioglu, A., Ozdemir, O., Eldem, B., Unlu, N., Alp, M.N., Saatci, A.O., Ozmert, E., Deger, C., Asan, S., Sumer, F., Parali, E., Ozel, M.O., Erdal, E., and Sar, C.
- Published
- 2015
- Full Text
- View/download PDF
28. PSS18 - Cost-effectiveness of Aflibercept in the treatment of Central Retinal Vein Occlusion in Turkey
- Author
-
Tunalioglu, A., Ozdemir, O., Eldem, B., Unlu, N., Alp, M.N., Saatci, A.O., Ozmert, E., Deger, C., Asan, S., Sumer, F., Parali, E., Ozel, M.O., Erdal, E., and Sar, C.
- Published
- 2015
- Full Text
- View/download PDF
29. Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: Pan-European experience
- Author
-
Sivaprasad, S, primary, Hykin, P, additional, Saeed, A, additional, Beatty, S, additional, Grisanti, S, additional, Staurenghi, G, additional, Olea, J L, additional, Campos, A, additional, Barbosa, A, additional, Rito, L, additional, Silva, R, additional, Faria, R, additional, Eldem, B, additional, Kadayıfçılar, S, additional, Kolar, P, additional, Feucht, N, additional, and Maestroni, L, additional
- Published
- 2009
- Full Text
- View/download PDF
30. Sympathetic Ophthalmia Associated with Ocular and Cerebral Vasculitis: An Angiographic and Radiologic Study
- Author
-
Kadayifçilar, S., primary, Irkeç, M., additional, and Eldem, B., additional
- Published
- 2003
- Full Text
- View/download PDF
31. Cerebellar ataxia associated with hypogonadotropic hypogonadism and chorioretinopathy: a poorly recognized association
- Author
-
Erdem, E., primary, Kiratli, H., additional, Erbaş, T., additional, Varli, K., additional, Eldem, B., additional, Akalin, S., additional, Tan, E., additional, Topaloglu, H., additional, and Gedikoglu, G., additional
- Published
- 1994
- Full Text
- View/download PDF
32. Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: Pan-European experience.
- Author
-
Sivaprasad, S., Hykin, P., Saeed, A., Beatty, S., Grisanti, S., Staurenghi, G., Olea, J. L., Campos, A., Barbosa, A., Rito, L., Silva, R., Faria, R., Eldem, B., Kadayıfçılar, S., Kolar, P., Feucht, N., and Maestroni, L.
- Subjects
RETINAL degeneration ,OPHTHALMOLOGY ,CATARACT ,ENDOTHELIAL growth factors ,VISUAL acuity - Abstract
PurposeTo evaluate visual outcomes in patients with neovascular age-related macular degeneration (NV-AMD) who were treated with pegaptanib sodium in European clinical ophthalmology practices.MethodsThirteen centres in eight European countries participated in this retrospective study. Medical records for patients with any angiographic subtype of subfoveal choroidal neovascularisation secondary to NV-AMD with visual acuities (study eye) of 20/40–20/320 treated with 0.3 mg pegaptanib as first-line treatment and with at least 24 weeks of follow-up were identified. Anonymised data reflecting at least 24 and up to 54 weeks of follow-up were recorded. Primary end points were visual acuity outcomes at weeks 24 and 54 compared with those reported at week 54 in the vascular endothelial growth factor (VEGF) Inhibition Study in Ocular Neovascularisation (VISION) trial.ResultsIn all, 253 patients were followed for at least 24 weeks; 62 patients completed 54 weeks of follow-up. A mean of 4.4 (SD, 1.8) pegaptanib injections were administered through 24 weeks. Compared with the VISION trial, the European experience showed that >90% of patients in the current cohort lost <15 letters from baseline at both time points compared with 70% in the VISION trial at 54 weeks. Pegaptanib was well tolerated with no reported cases of endophthalmitis, traumatic cataract, or iatrogenic retinal detachment.ConclusionsPegaptanib was found to stabilise vision in a greater percentage of patients and produced greater overall visual improvement in this group of treatment-naive patients with NV-AMD compared with outcomes reported in the VISION trial; however, interpretation of these results should be tempered given the differences in design between this retrospective study and the prospective controlled trial. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
33. Symmetry of disciform scars in bilateral age-related macular degeneration.
- Author
-
Lavin, M J, primary, Eldem, B, additional, and Gregor, Z J, additional
- Published
- 1991
- Full Text
- View/download PDF
34. Cataract surgery in patients with Behcet`s disease
- Author
-
Kadayifcilar, S., Gedik, S., Eldem, B., and Irkec, M.
- Published
- 2002
- Full Text
- View/download PDF
35. PSS22 - The Cost-Of-Disease (Cod) In Wet Age-Related Macular Degeneration (Wamd) In Turkey: An Expert Panel Approach for Estimation of Costs
- Author
-
Deger, C, Ozdemir, O, Eldem, B, Unlu, N, Alp, MN, Saatci, AO, Ozmert, E, Erdal, E, Sar, C, Asan, S, Sumer, F, Parali, E, and Ozel, O
- Published
- 2015
- Full Text
- View/download PDF
36. PSS19 - The Cost-Of-Disease (Cod) In Diabetic Macular Edema (Dme) In Turkey: An Expert Panel Approach for Estimation of Costs
- Author
-
Deger, C, Ozdemir, O, Eldem, B, Unlu, N, Alp, MN, Saatci, AO, Ozmert, E, Altintas, AK, Sermet, F, Erdal, E, Sar, C, Asan, S, Sumer, F, Parali, E, and Ozel, O
- Published
- 2015
- Full Text
- View/download PDF
37. PSS21 - The Cost-Of-Disease (Cod) In Central Retinal Vein Occlusion (Crvo) In Turkey: An Expert Panel Approach For Estimation of Costs
- Author
-
Deger, C, Ozdemir, O, Eldem, B, Unlu, N, Alp, MN, Saatci, AO, Ozmert, E, Erdal, E, Sar, C, Asan, S, Sumer, F, Parali, E, and Ozel, O
- Published
- 2015
- Full Text
- View/download PDF
38. Uveitis in childhood
- Author
-
Kadayifcilar, S., Eldem, B., and Tumer, B.
- Published
- 2004
- Full Text
- View/download PDF
39. Scedosporium apiospermum chorioretinitis
- Author
-
Kıratl, ALT="inodot">, H. SRC="/iso-ents/isolat2/inodot-s.gif", Ö., Uzun, Kiraz, N., and Eldem, B.
- Abstract
.Purpose: A case of a 24-year-old immunocompetent woman who developed unilateral Scedosporium apiospermum chorioretinitis and diffuse cervical lymphadenitis 10 years after facial steroid injection is described.Methods: The patient was initially treated for the misdiagnosis of tuberculous lymphadenitis. Contemporaneous to the enlargement of her lymph nodes, she experienced gradual loss of vision in her left eye. She subsequently underwent lymph node biopsy.Results: Histopathologic sections stained with Grocott's methenamine silver showed branched septate hyphae and cultures on Sabouraud's agar yielded Scedosporium apiospermum. The patient received oral itraconazole 200 mg twice daily. Lymphadenitis regressed within a year and chorioretinitis scarred within two years.Conclusion: Scedosporium apiospermum may cause isolated chorioretinitis in an immunocompetent individual years after local surgery or trauma and result in significant visual morbidity. Treatment may require prolonged use of systemic itraconazole.
- Published
- 2001
- Full Text
- View/download PDF
40. Retinitis pigmentosa associated with peripheral sea fan neovascularization
- Author
-
Kadayıfç, ALT="inodot">lar, S. SRC="/iso-ents/isolat2/inodot-s.gif", Eldem, B., Kıratl, and ALT="inodot">, H. SRC="/iso-ents/isolat2/inodot-s.gif"
- Abstract
.Purpose: To describe a case with retinitis pigmentosa associated with sea fan type retinal neovascularization.Methods: Complete ocular examination including fluorescein angiography was performed in a 9-year-old girl.Results: Ophthalmoscopically, in addition to arteriolar narrowing and bone corpuscular pigmentation of both retinae, a vascular lesion with surrounding intraretinal exudation was noted in the upper equatorial region of the right eye. On fluorescein angiography, the lesion stained in the form of a sea fan neovascularization.Conclusion: Sea fan type of neovascularization can be seen in association with retinitis pigmentosa. Fluorescein angiography is important in identifying the exact nature of such a lesion.
- Published
- 2000
- Full Text
- View/download PDF
41. PSS22 The Cost-Of-Disease (Cod) In Wet Age-Related Macular Degeneration (Wamd) In Turkey: An Expert Panel Approach for Estimation of Costs
- Author
-
Deger, C, Ozdemir, O, Eldem, B, Unlu, N, Alp, MN, Saatci, AO, Ozmert, E, Erdal, E, Sar, C, Asan, S, Sumer, F, Parali, E, and Ozel, O
- Subjects
stomatognathic system ,technology, industry, and agriculture - Full Text
- View/download PDF
42. PSS18 Cost-effectiveness of Aflibercept in the treatment of Central Retinal Vein Occlusion in Turkey
- Author
-
Tunalioglu, A., Ozdemir, O., Eldem, B., Unlu, N., Alp, M.N., Saatci, A.O., Ozmert, E., Deger, C., Asan, S., Sumer, F., Parali, E., Ozel, M.O., Erdal, E., and Sar, C.
- Full Text
- View/download PDF
43. PDB51 The Cost-Effectiveness (CE) of Intravitreal Aflibercept (IVT-AFL) in the Treatment of Diabetic Macular Edema (DME) in Turkey
- Author
-
Deger, C, Ozdemir, O, Eldem, B, Unlu, N, Alp, MN, Saatci, AO, Ozmert, E, Altintas, AK, Sermet, F, Erdal, E, Sar, C, Asan, S, Sumer, F, Parali, E, and Ozel, O
- Full Text
- View/download PDF
44. PSS21 Cost-effectiveness of Aflibercept in the treatment of wet age-related Macular Degeneration in Turkey
- Author
-
Tunalioglu, A., Ozdemir, O., Eldem, B., Unlu, N., Alp, M.N., Saatci, A.O., Ozmert, E., Deger, C., Asan, S., Sumer, F., Parali, E., Ozel, M.O., Erdal, E., and Sar, C.
- Full Text
- View/download PDF
45. PSS21 The Cost-Of-Disease (Cod) In Central Retinal Vein Occlusion (Crvo) In Turkey: An Expert Panel Approach For Estimation of Costs
- Author
-
Deger, C, Ozdemir, O, Eldem, B, Unlu, N, Alp, MN, Saatci, AO, Ozmert, E, Erdal, E, Sar, C, Asan, S, Sumer, F, Parali, E, and Ozel, O
- Subjects
stomatognathic system ,technology, industry, and agriculture - Full Text
- View/download PDF
46. PSS19 The Cost-Of-Disease (Cod) In Diabetic Macular Edema (Dme) In Turkey: An Expert Panel Approach for Estimation of Costs
- Author
-
Deger, C, Ozdemir, O, Eldem, B, Unlu, N, Alp, MN, Saatci, AO, Ozmert, E, Altintas, AK, Sermet, F, Erdal, E, Sar, C, Asan, S, Sumer, F, Parali, E, and Ozel, O
- Subjects
stomatognathic system ,technology, industry, and agriculture - Full Text
- View/download PDF
47. Behçet's disease and interferon: flaws in research integrity of randomised trial.
- Author
-
Eldem, B
- Subjects
- *
AUTHORSHIP , *BEHCET'S disease , *CLINICAL trials , *MEDICAL ethics , *RESEARCH personnel - Published
- 2000
- Full Text
- View/download PDF
48. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial
- Author
-
Riccardo Masson, Maria Mazurkiewicz-Bełdzińska, Kristy Rose, Laurent Servais, Hui Xiong, Edmar Zanoteli, Giovanni Baranello, Claudio Bruno, John W Day, Nicolas Deconinck, Andrea Klein, Eugenio Mercuri, Dmitry Vlodavets, Yi Wang, Angela Dodman, Muna El-Khairi, Ksenija Gorni, Birgit Jaber, Heidemarie Kletzl, Eleni Gaki, Paulo Fontoura, Basil T Darras, Joseph J Volpe, John Posner, Ulrich Kellner, Rosaline Quinlivan, Marianne Gerber, Omar Khwaja, Renata S Scalco, Timothy Seabrook, Armin Koch, Irina Balikova, Inge Joniau, Geraldine Accou, Valentine Tahon, Sylvia Wittevrongel, Elke De Vos, Rodrigo de Holanda Mendonça, Ciro Matsui Jr, Ana Letícia Fornazieri Darcie, Cleide Machado, Maria Kiyoko Oyamada, Joyce Martini, Graziela Polido, Juliana Rodrigues Iannicelli, Juliana Caires de Oliveira Achili Ferreira, Chaoping Hu, Xiaomei Zhu, Chen Qian, Li Shen, Hui Li, Yiyun Shi, Shuizhen Zhou, Ying Xiao, Zhenxuan Zhou, Sujuan Wang, Tian Sang, Cuijie Wei, Hui Dong, Yiwen Cao, Jing Wen, Wenzhu Li, Lun Qin, Nina Barisic, Ivan Celovec, Martina Galiot Delic, Petra Kristina Ivkic, Nenad Vukojevic, Ivana Kern, Boris Najdanovic, Marin Skugor, Josipa Tomas, Odile Boespflug-Tanguy, Silvana De Lucia, Andrea Seferian, Emmanuel Barreau, Nabila Mnafek, Helene Peche, Allison Grange, Diem Trang Nguyen, Darko Milascevic, Shotaro Tachibana, Emanuela Pagliano, Stefania Bianchi Marzoli, Diletta Santarsiero, Myriam Garcia Sierra, Gemma Tremolada, Maria Teresa Arnoldi, Marta Vigano, Claudia Dosi, Riccardo Zanin, Veronica Schembri, Noemi Brolatti, Giuseppe Rao, Elisa Tassara, Simone Morando, Paola Tacchetti, Marina Pedemonte, Enrico Priolo, Lorenza Sposetti, Giacomo Pietro Comi, Alessandra Govoni, Silvia Gabriella Osnaghi, Valeria Minorini, Francesca Abbati, Federica Fassini, Michaela Foa, Amalia Lopopolo, Marika Pane, Concetta Palermo, Maria Carmela Pera, Giulia Maria Amorelli, Costanza Barresi, Guglielmo D'Amico, Lorenzo Orazi, Giorgia Coratti, Daniela Leone, Antonaci Laura, Roberto De Sanctis, Beatrice Berti, Naoki Kimura, Yasuhiro Takeshima, Hideki Shimomura, Tomoko Lee, Fumi Gomi, Takanobu Morimatsu, Toru Furukawa, Urszula Stodolska-Koberda, Agnieszka Waskowska, Jagoda Kolendo, Agnieszka Sobierajska-Rek, Sandra Modrzejewska, Anna Lemska, Evgenia Melnik, Svetlana Artemyeva, Natalya Leppenen, Nataliya Yupatova, Anastasya Monakhova, Yulia Papina, Olga Shidlovsckaia, Elena Litvinova, Cornelia Enzmann, Elea Galiart, Konstantin Gugleta, Christine Wondrusch Haschke, Haluk Topaloglu, Ibrahim Oncel, Nesibe Eroglu Ertugrul, Bahadir Konuskan, Bora Eldem, Sibel Kadayifçilar, Ipek Alemdaroglu, Seher Sari, Neslihan Bilgin, Aynur Ayse Karaduman, Fatma Gokcem Yildiz Sarikaya, Robert J Graham, Partha Ghosh, David Casavant, Alexis Levine, Rachael Titus, Amanda Engelbrekt, Lucia Ambrosio, Anne Fulton, Anna Maria Baglieri, Courtney Dias, Elizabeth Maczek, Amy Pasternak, Shannon Beres, Tina Duong, Richard Gee, Sally Young, Masson, R., Mazurkiewicz-Beldzinska, M., Rose, K., Servais, L., Xiong, H., Zanoteli, E., Baranello, G., Bruno, C., Day, J. W., Deconinck, N., Klein, A., Mercuri, E., Vlodavets, D., Wang, Y., Dodman, A., El-Khairi, M., Gorni, K., Jaber, B., Kletzl, H., Gaki, E., Fontoura, P., Darras, B. T., Volpe, J. J., Posner, J., Kellner, U., Quinlivan, R., Gerber, M., Khwaja, O., Scalco, R. S., Seabrook, T., Koch, A., Balikova, I., Joniau, I., Accou, G., Tahon, V., Wittevrongel, S., De Vos, E., de Holanda Mendonca, R., Matsui Jr, C., Fornazieri Darcie, A. L., Machado, C., Kiyoko Oyamada, M., Martini, J., Polido, G., Rodrigues Iannicelli, J., Caires de Oliveira Achili Ferreira, J., Hu, C., Zhu, X., Qian, C., Shen, L., Li, H., Shi, Y., Zhou, S., Xiao, Y., Zhou, Z., Wang, S., Sang, T., Wei, C., Dong, H., Cao, Y., Wen, J., Li, W., Qin, L., Barisic, N., Celovec, I., Galiot Delic, M., Ivkic, P. K., Vukojevic, N., Kern, I., Najdanovic, B., Skugor, M., Tomas, J., Boespflug-Tanguy, O., De Lucia, S., Seferian, A., Barreau, E., Mnafek, N., Peche, H., Grange, A., Trang Nguyen, D., Milascevic, D., Tachibana, S., Pagliano, E., Bianchi Marzoli, S., Santarsiero, D., Garcia Sierra, M., Tremolada, G., Arnoldi, M. T., Vigano, M., Dosi, C., Zanin, R., Schembri, V., Brolatti, N., Rao, G., Tassara, E., Morando, S., Tacchetti, P., Pedemonte, M., Priolo, E., Sposetti, L., Comi, G. P., Govoni, A., Osnaghi, S. G., Minorini, V., Abbati, F., Fassini, F., Foa, M., Lopopolo, A., Pane, M., Palermo, C., Pera, M. C., Amorelli, G. M., Barresi, C., D'Amico, G., Orazi, L., Coratti, G., Leone, D., Laura, A., De Sanctis, R., Berti, B., Kimura, N., Takeshima, Y., Shimomura, H., Lee, T., Gomi, F., Morimatsu, T., Furukawa, T., Stodolska-Koberda, U., Waskowska, A., Kolendo, J., Sobierajska-Rek, A., Modrzejewska, S., Lemska, A., Melnik, E., Artemyeva, S., Leppenen, N., Yupatova, N., Monakhova, A., Papina, Y., Shidlovsckaia, O., Litvinova, E., Enzmann, C., Galiart, E., Gugleta, K., Wondrusch Haschke, C., Topaloglu, H., Oncel, I., Ertugrul, N. E., Konuskan, B., Eldem, B., Kadayifcilar, S., Alemdaroglu, I., Sari, S., Bilgin, N., Karaduman, A. A., Sarikaya, F. G. Y., Graham, R. J., Ghosh, P., Casavant, D., Levine, A., Titus, R., Engelbrekt, A., Ambrosio, L., Fulton, A., Baglieri, A. M., Dias, C., Maczek, E., Pasternak, A., Beres, S., Duong, T., Gee, R., and Young, S.
- Subjects
Muscular Atrophy, Spinal ,Settore MED/26 - NEUROLOGIA ,Pyrimidines ,Settore MED/39 - NEUROPSICHIATRIA INFANTILE ,Settore MED/48 - SCIENZE INFERMIERISTICHE E TECNICHE NEURO-PSICHIATRICHE E RIABILITATIVE ,Humans ,Infant ,Neurology (clinical) ,Spinal Muscular Atrophies of Childhood ,Azo Compounds ,spinal muscular atrophy - Abstract
Background: Risdiplam is an orally administered therapy that modifies pre-mRNA splicing of the survival of motor neuron 2 (SMN2) gene and is approved for the treatment of spinal muscular atrophy. The FIREFISH study is investigating the safety and efficacy of risdiplam in treated infants with type 1 spinal muscular atrophy versus historical controls. The primary endpoint of part 2 of the FIREFISH study showed that infants with type 1 spinal muscular atrophy attained the ability to sit without support for at least 5 s after 12 months of treatment. Here, we report on the safety and efficacy of risdiplam in FIREFISH part 2 over 24 months of treatment. Methods: FIREFISH is an ongoing, multicentre, open-label, two-part study. In FIREFISH part 2, eligible infants (aged 1-7 months at enrolment, with a genetically confirmed diagnosis of spinal muscular atrophy, and two SMN2 gene copies) were enrolled in 14 hospitals in ten countries across Europe, North America, South America, and Asia. Risdiplam was orally administered once daily at 0·2 mg/kg for infants between 5 months and 2 years of age; once an infant reached 2 years of age, the dose was increased to 0·25 mg/kg. Infants younger than 5 months started at 0·04 mg/kg (infants between 1 month and 3 months old) or 0·08 mg/kg (infants between 3 months and 5 months old), and this starting dose was adjusted to 0·2 mg/kg once pharmacokinetic data were available for each infant. The primary and secondary endpoints included in the statistical hierarchy and assessed at month 12 have been reported previously. Here we present the remainder of the secondary efficacy endpoints that were included in the statistical hierarchy at month 24: the ability to sit without support for at least 30 s, to stand alone, and to walk alone, as assessed by the Bayley Scales of Infant and Toddler Development, third edition gross motor subscale. These three endpoints were compared with a performance criterion of 5% that was defined based on the natural history of type 1 spinal muscular atrophy; the results were considered statistically significant if the lower limit of the two-sided 90% CI was above the 5% threshold. FIREFISH is registered with ClinicalTrials.gov, NCT02913482. Recruitment is closed; the 36-month extension period of the study is ongoing. Findings: Between March 13 and Nov 19, 2018, 41 infants were enrolled in FIREFISH part 2. After 24 months of treatment, 38 infants were ongoing in the study and 18 infants (44% [90% CI 31-58]) were able to sit without support for at least 30 s (p
- Published
- 2022
49. Fundamental principles of an effective diabetic retinopathy screening program
- Author
-
Lanzetta, Paolo, Sarao, Valentina, Scanlon, Peter H, Barratt, Jane, Porta, Massimo, Bandello, Francesco, Loewenstein, Anat, Eldem, Bora, Hunyor, Alex, Joussen, Antonia, Koh, Adrian, Korobelnik, Jean-François, Lövestam-Adrian, Monica, Navarro, Rafael, Okada, Annabelle A., Pearce, Ian, Rodríguez, Francisco J., Staurenghi, Giovanni, Wolf, Sebastian, Wong, David T., Lanzetta, P., Sarao, V., Scanlon, P. H., Barratt, J., Porta, M., Bandello, F., Loewenstein, A., Eldem, B., Hunyor, A., Joussen, A., Koh, A., Korobelnik, J. -F., Lovestam-Adrian, M., Navarro, R., Okada, A. A., Pearce, I., Rodriguez, F. J., Staurenghi, G., Wolf, S., and Wong, D. T.
- Subjects
Adult ,Male ,Telemedicine ,Consensus ,Endocrinology, Diabetes and Metabolism ,Diabetic macular edema ,Early detection ,030209 endocrinology & metabolism ,Macular Edema ,Diabetic retinopathy screening ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Evidence-based recommendations ,Internal Medicine ,medicine ,Diabetes Mellitus ,Humans ,Mass Screening ,Grading (education) ,Referral and Consultation ,Accreditation ,Diabetic Retinopathy ,business.industry ,General Medicine ,Diabetic retinopathy ,Middle Aged ,medicine.disease ,RA645.D54 ,Systematic review ,Practice Guidelines as Topic ,030221 ophthalmology & optometry ,RE ,Female ,Medical emergency ,business ,Program Evaluation - Abstract
Background Diabetic retinopathy (DR) is the leading cause of blindness among working-age adults worldwide. Early detection and treatment are necessary to forestall vision loss from DR. Methods A working group of ophthalmic and diabetes experts was established to develop a consensus on the key principles of an effective DR screening program. Recommendations are based on analysis of a structured literature review. Results The recommendations for implementing an effective DR screening program are: (1) Examination methods must be suitable for the screening region, and DR classification/grading systems must be systematic and uniformly applied. Two-field retinal imaging is sufficient for DR screening and is preferable to seven-field imaging, and referable DR should be well defined and reliably identifiable by qualified screening staff; (2) in many countries/regions, screening can and should take place outside the ophthalmology clinic; (3) screening staff should be accredited and show evidence of ongoing training; (4) screening programs should adhere to relevant national quality assurance standards; (5) studies that use uniform definitions of risk to determine optimum risk-based screening intervals are required; (6) technology infrastructure should be in place to ensure that high-quality images can be stored securely to protect patient information; (7) although screening for diabetic macular edema (DME) in conjunction with DR evaluations may have merit, there is currently insufficient evidence to support implementation of programs solely for DME screening. Conclusion Use of these recommendations may yield more effective DR screening programs that reduce the risk of vision loss worldwide.
- Published
- 2020
50. Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial.
- Author
-
Demiroglu, Haluk, Ozcebe, Osman I., Barista, Ibrahim, Dundar, Semra, Eldem, Bora, Demiroglu, H, Ozcebe, O I, Barista, I, Dündar, S, and Eldem, B
- Subjects
- *
EYE disease prevention , *BEHCET'S disease , *THERAPEUTIC use of interferons , *VISION , *PATIENTS , *PHYSIOLOGY - Abstract
Background: Sight-threatening eye involvement is a serious complication of Behçet's disease. Extraocular complications such as arthritis, vascular occlusive disorders, mucocutaneous lesions, and central-nervous-system disease may lead to morbidity and even death. We designed a prospective study in newly diagnosed patients without previous eye disease to assess whether prevention of eye involvement and extraocular manifestations, and preservation of visual acuity are possible with combination treatments with and without interferon alfa-2b.Methods: Patients were randomly assigned 3 million units interferon alfa-2b subcutaneously every other day for the first 6 months plus 1.5 mg colchicine orally daily and 1.2 million units benzathine penicillin intramuscularly every 3 weeks (n=67), or colchicine and benzathine penicillin alone (n=68). The primary endpoint was visual-acuity loss. Analysis was by intention to treat.Findings: Significantly fewer patients who were treated with interferon had eye involvement than did patients who did not receive interferon (eight vs 27, relative risk 0.21 [95% CI 0.09-0.50], p<0.001). Ocular attack rate was 0.2 (SD 0.62) per year with interferon therapy and 1.02 (1.13) without interferon therapy (p=0.0001). Visual-acuity loss was significantly lower among patients treated with interferon than in those without interferon (two vs 13, relative risk 0.13 [95% CI 0.03-0.60], p=0.003). Arthritis episodes, vascular events, and mucocutaneous lesions were also less frequent in patients treated with interferon than in those not receiving interferon. No serious side-effects were reported.Interpretation: Therapy with interferon alfa-2b, colchicine, and benzathine penicillin seems to be an effective regimen in Behçet's disease for the prevention of recurrent eye attacks and extraocular complications, and for the protection of vision. [ABSTRACT FROM AUTHOR]- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.